Anti-tumor immune priming

Anti-tumor immune priming refers to the biological process where the immune system, typically through antigen-presenting cells (APCs) such as dendritic cells, initiates and "primes" an adaptive immune response against tumor antigens. This process involves the uptake and presentation of tumor-derived antigens, activation and maturation of APCs, and subsequent activation and proliferation of tumor-specific T lymphocytes (CD4+ and CD8+ T cells)[1][2][3]. Effective anti-tumor immune priming is crucial for the success of many immunotherapies, including immune checkpoint inhibitors, as it determines whether the immune system can recognize and attack cancer cells. Although not a direct therapeutic target, the process of immune priming is frequently enhanced or manipulated by various therapeutic interventions such as checkpoint blockade, vaccination, and combination therapies with agents like HSP90 inhibitors and radiation[1][3][6]. Impairments in immune priming contribute to poor responses in some tumor settings, and research continues to focus on understanding and overcoming barriers to effective anti-tumor immune activation[1][4][5].

Other names

anti-tumour immune primingantitumor immune primingpriming of anti-tumor immune response

Promotion of dendritic cell recruitment and activation; Enhancement of T cell (especially CD8+ and CD4+) priming and clonal expansion[1][2][3]; Release of damage-associated molecular patterns to stimulate antigen-presenting cells[3]